Replies to post #4746 on Antares Pharma, Inc. (ATRS)

[ou71764]

I don't have a subscription to SOS. I didn't see any indication that he had a recent update. I made another small purchase of a few more shares of ATRS. Not sure what the future holds for ATRS, but imo it's more than just Xyosted. I have tempered my expectations for the stock price in 2020 but I'm still bullish and long the stock.

[hyperopia]

Hi again CN. No updates from Larry Smith, but I’m guessing there will be one in a few weeks, maybe after Antares reports their fourth quarter and full year results and the 10-K is filed. BTW- they haven’t cut forecasts, they only provided conservative guidance of about 20% growth. Based on the prescription data, I think Antares will at least break even or earn a small profit this quarter, (a penny) and I anticipate at least modest growth and profitability going forward. The stock price doesn’t always reflect the value of these small companies, but turning the profitability corner is a big positive, and after the recent sell-off, I think ATRS is undervalued. When the uncertainty about the status of Makena and timing of the generic Forteo launch are known, (Teva now says end of 2020 or early 2021) it could give the shares a lift. A little clarity on the pipeline would also help and that should also be known soon. As far as the slowing growth of Xyosted, I think it’s just temporary, and growth will pick back up, but there’s only so much you can do with their limited sales staff and budget.

I’ve always been a long-term investor, but after watching paper profits washed away with these small companies, (ATRS, BLFS & CYRX, etc.) in the last few years, I’ve become more of a long-term trader due to the volatility and games that are played with these stocks. By buying when the price is low (like after the CRL & now) you can then sell individual lots when the price appreciates. Like the old saying goes - If you can’t beat ‘em, join ‘em.